Medical imaging company Median Technologies has launched a new business unit that will provide decision-making tools — powered by artificial intelligence — to sponsors of clinical trials in oncology.
Median said the new Imaging Lab will deploy artificial intelligence, data mining and radiology technologies into medical imaging data generated in cancer trials.
The new unit will build on Median’s iBiopsy platform – a software as a medical device (SaMD) being developed for a range of diagnostic procedures in oncology including lung cancer screening, liver cancer diagnosis and recurrence prediction – and the iCRO Contract Research business unit focused on image management in Clinical trials.
The company said the Imaging Lab will provide a toolkit increasingly relevant to the development of new cancer treatments, as the biopharmaceutical industry increasingly focuses on drugs to detect and treat cancer at an early stage.
Median said last month that it was preparing to apply for Food and Drug Administration approval of iBiopsy for lung cancer screening, with the goal of getting a green light for SaMD before the end of 2023, based on study data showing a sensitivity of 94.7% and specificity of 93.3% in detecting cancer in lung nodules. From a group of 1760 patients.
The platform can be used to select patients for inclusion in clinical trials, particularly studies aimed at including patients diagnosed with an early-stage disease, as well as to predict response to treatment, measure disease progression, and evaluate the safety of candidate drugs, the mediator said.
The hope is that using iBiopsy in trials will speed up go/no-go decisions, raising the success rate of trials that are particularly low in oncology, according to the company.
It costs an average of $2.8 billion to bring a new cancer drug to market, it said, compared to $1 billion for new drugs in other treatment classes, citing data from a 2020 analysis published in the Journal of the American Medical Association.
“Our experience with image management in clinical trials has shown that trial data is largely underutilized,” said Nicholas Dano, COO, iCRO at Median.
“We can extract more information from images through the widespread use of data mining, artificial intelligence, and radioscience, and use these technologies to better support our customers and biopharmaceutical partners in their clinical developments,” he added.
#Median #Tech #launches #AIfocused #unit #support #cancer #trials